MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016)

Phase 2 Completed 55 enrolled Merck Sharp & Dohme LLC

RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to determine the safety and effectiveness of an investigational drug MK0249 for the treatment of the cognitive impairment in patients with schizophrenia.

Timeline

Start: 2007-12
Primary completion: 2008-10
Completion: 2008-10

Outcome

Missed primary endpoint

paper MK-0249 10mg once daily was not superior to placebo in the treatment of cognitive impairment in patients with schizophrenia after 4-weeks. PMID 23523692 ↗

registry analysis (superiority or other test); MK0249 vs Placebo; p = 0.939; constrained longitudinal data analysis; NCT00506077 ↗

Publications

F Egan M, Zhao X, Gottwald R, Harper-Mozley L, Zhang Y, Snavely D, Lines C, Michelson D. Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia. Schizophr Res. 2013 May;146(1-3):224-30. doi: 10.1016/j.schres.2013.02.030. Epub 2013 Mar 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MK-0249	Small molecule	10 mg	—